PubRank

A Clinton White

Author PubWeight™ 101.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007 10.66
2 Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005 5.08
3 Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002 3.37
4 Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care 2005 2.64
5 The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005 2.43
6 Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr 2003 2.33
7 Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia 2014 2.11
8 New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg 2005 2.10
9 Neuroendoscopic diagnosis of central nervous system histoplasmosis with basilar arachnoiditis. World Neurosurg 2011 2.05
10 An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am 2006 2.05
11 Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis 2012 1.95
12 Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett 2010 1.82
13 Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004 1.74
14 Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis 2005 1.72
15 Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 2016 1.66
16 A positive enzyme-linked immunoelectrotransfer blot assay result for a patient without evidence of cysticercosis. Clin Infect Dis 2002 1.49
17 Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg 2009 1.41
18 Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg 2005 1.30
19 Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg 2010 1.29
20 Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis 2010 1.29
21 Zoonotic larval cestode infections: neglected, neglected tropical diseases? PLoS Negl Trop Dis 2009 1.26
22 A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis 2013 1.23
23 Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 2009 1.23
24 Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol 2007 1.23
25 Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) 2011 1.19
26 Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 2002 1.18
27 Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007 1.17
28 Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003 1.12
29 Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett 2012 1.12
30 Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007 1.10
31 Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis. AIDS 2002 1.08
32 Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am 2012 1.05
33 Foxp3+ regulatory T cells in antiretroviral-naive HIV patients. AIDS 2006 1.04
34 Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 2008 1.02
35 Interleukin-8, tumor necrosis factor-alpha, and lactoferrin in immunocompetent hosts with experimental and Brazilian children with acquired cryptosporidiosis. Am J Trop Med Hyg 2003 1.01
36 Enteropathogens and chronic illness in returning travelers. N Engl J Med 2013 0.99
37 Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J Infect Dis 2005 0.99
38 Neurocysticercosis in the United States. Pathog Glob Health 2012 0.98
39 Cryptosporidium infection of human intestinal epithelial cells increases expression of osteoprotegerin: a novel mechanism for evasion of host defenses. J Infect Dis 2008 0.94
40 Intestinal immune response to human Cryptosporidium sp. infection. Infect Immun 2007 0.93
41 Human CD8(+) T cells clear Cryptosporidium parvum from infected intestinal epithelial cells. Am J Trop Med Hyg 2010 0.92
42 Sequential expression of the neuropeptides substance P and somatostatin in granulomas associated with murine cysticercosis. Infect Immun 2002 0.91
43 Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther 2006 0.90
44 Seropositive human subjects produce interferon gamma after stimulation with recombinant Cryptosporidium hominis gp15. Am J Trop Med Hyg 2007 0.90
45 Treatment of cryptosporidiosis. Expert Rev Anti Infect Ther 2009 0.89
46 Burden of Fasciola hepatica Infection among children from Paucartambo in Cusco, Peru. Am J Trop Med Hyg 2012 0.88
47 Epileptogenic activity of granulomas associated with murine cysticercosis. Exp Neurol 2003 0.88
48 Nitazoxanide: an important advance in anti-parasitic therapy. Am J Trop Med Hyg 2003 0.88
49 Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection. Infect Immun 2013 0.87
50 Cryopreservation modulates the detection of regulatory T cell markers. Cytometry B Clin Cytom 2011 0.86
51 Workshop report: Developing an international collaborative research network in neurocysticercosis and epilepsy. Epilepsia 2009 0.86
52 Neurocysticercosis in the HIV era: a case report and review of the literature. Am J Trop Med Hyg 2007 0.85
53 New developments in epidemiology, diagnosis, and treatment of fascioliasis. Curr Opin Infect Dis 2012 0.85
54 Characterization of excretory/secretory endopeptidase and metallo-aminopeptidases from Taenia crassiceps metacestodes. J Parasitol 2005 0.84
55 Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004 0.84
56 Travelers' diarrhea: an update on susceptibility, prevention, and treatment. Curr Gastroenterol Rep 2008 0.83
57 High levels of CXCL10 are produced by intestinal epithelial cells in AIDS patients with active cryptosporidiosis but not after reconstitution of immunity. Infect Immun 2006 0.82
58 Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy. J Infect Dis 2010 0.82
59 Substance P expression correlates with severity of diarrhea in cryptosporidiosis. J Infect Dis 2003 0.81
60 A single-nucleotide polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with diarrheagenic Escherichia coli, is associated with an increased risk of nonsecretory bacterial diarrhea in North American travelers to Mexico. J Infect Dis 2009 0.81
61 Protection from murine cysticercosis by immunization with a parasite cysteine protease. Microbes Infect 2006 0.80
62 Acute mountain sickness impact among travelers to Cusco, Peru. J Travel Med 2012 0.79
63 Nitazoxanide for treatment of intestinal parasites in children. Pediatr Infect Dis J 2005 0.79
64 Symptoms of intestinal schistosomiasis presenting during treatment of large B cell lymphoma. Am J Trop Med Hyg 2004 0.79
65 Oligonucleotide-gold nanoparticle networks for detection of Cryptosporidium parvum heat shock protein 70 mRNA. J Clin Microbiol 2009 0.79
66 Treatable bacterial infections are underrecognized causes of fever in Ethiopian children. Am J Trop Med Hyg 2012 0.79
67 Proinflammatory cytokines in granulomas associated with murine cysticercosis are not the cause of seizures. J Parasitol 2006 0.78
68 Management of potential neurocysticercosis in patients with HIV infection. Clin Infect Dis 2006 0.78
69 Human studies provide insight into the pathogenesis, immunology, and treatment of cryptosporidiosis. Clin Infect Dis 2003 0.77
70 Capillaria hepatica pseudoinfection. Am J Trop Med Hyg 2013 0.77
71 Microsporidiasis. Handb Clin Neurol 2013 0.76
72 Cryptosporidiosis and the ears of the hippopotamus. Clin Infect Dis 2010 0.76
73 Cysteine proteinase inhibitors in murine cysticercosis. Antimicrob Agents Chemother 2006 0.75
74 Why are there seizures in neurocysticercosis: is it in the genes? J Infect Dis 2010 0.75
75 Hemorrhagic cerebrovascular events and neurocysticercosis: a case report and review of the literature. Am J Trop Med Hyg 2011 0.75
76 CD4+ T cell subsets and Tax expression in HTLV-1 associated diseases. Pathog Glob Health 2013 0.75
77 Altered eosinophil proteome in a patient with hypereosinophilia from acute fascioliasis. Clin Vaccine Immunol 2011 0.75
78 Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens. J Acquir Immune Defic Syndr 2003 0.75
79 Unusual manifestations of disseminated Histoplasmosis in patients responding to antiretroviral therapy. Am J Med 2005 0.75
80 Treatment of chronic cryptosporidiosis in AIDS with rIL-12 induces an immune response associated with improvement but severe side-effects. AIDS 2005 0.75
81 We are (at risk with) what we eat. Curr Opin Infect Dis 2016 0.75